Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

2,3,5-Trimethoxyamphetamine

From Wikipedia, the free encyclopedia
(Redirected fromTMA-4 (psychedelic))

Pharmaceutical compound
TMA-4
Clinical data
Other names2,3,5-TMA; TMA-4
Routes of
administration
Oral[1]
Drug classSerotonin receptor modulator;Serotonergic psychedelic;Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action~6 hours[1]
Identifiers
  • 1-(2,3,5-trimethoxyphenyl)propan-2-amine
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC12H19NO3
Molar mass225.288 g·mol−1
3D model (JSmol)
  • CC(CC1=C(C(=CC(=C1)OC)OC)OC)N
  • InChI=1S/C12H19NO3/c1-8(13)5-9-6-10(14-2)7-11(15-3)12(9)16-4/h6-8H,5,13H2,1-4H3
  • Key:MJIBJXKJBRLSQA-UHFFFAOYSA-N

2,3,5-Trimethoxyamphetamine (2,3,5-TMA), also known asTMA-4, is apsychedelic drug of thephenethylamine andamphetamine families.[1][2] It is one of the possiblepositional isomers oftrimethoxyamphetamine and is a positional isomer of3,4,5-trimethoxyamphetamine (TMA or TMA-1).[1][2]

Use and effects

[edit]

In his bookPiHKAL (Phenethylamines I Have Known and Loved) and other publications,Alexander Shulgin lists 2,3,5-TMA's dose as greater than 80 mgorally and itsduration as perhaps or about 6 hours.[1][3][4] Based on limited testing, it produced threshold effects including muchintrospection among others, along with no subjectivephysical symptoms.[1][2] The drug at 80 mg was described as comparable to 50 μgLSD or 120 mg TMA and as being roughly 4-fold aspotent asmescaline.[1][2] Per Shulgin, more testing is needed to fully characterize the drug in humans.[1]

Interactions

[edit]
See also:Psychedelic drug § Interactions, andTrip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]

Pharmacodynamics

[edit]

2,3,5-TMA showsaffinity forserotonin receptors.[2][5][6] The drug substitutes forDOM in rodentdrug discrimination tests.[2][7]

Chemistry

[edit]

Synthesis

[edit]

Thechemical synthesis of 2,3,5-TMA has been described.[1][2]

History

[edit]

2,3,5-TMA was first described in thescientific literature byAlexander Shulgin in 1966.[8] Subsequently, it was described in greater detail by Shulgin in his 1991 bookPiHKAL (Phenethylamines I Have Known and Loved).[1]

Society and culture

[edit]

Legal status

[edit]

Canada

[edit]

2,3,5-TMA is acontrolled substance inCanada under phenethylamine blanket-ban language.[9]

United States

[edit]

As apositional isomer of3,4,5-trimethoxyamphetamine (TMA), 2,3,5-TMA is aSchedule Icontrolled substance in theUnited States.[2]

See also

[edit]

References

[edit]
  1. ^abcdefghijShulgin A,Shulgin A (September 1991).PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press.ISBN 0-9630096-0-5.OCLC 25627628.https://erowid.org/library/books_online/pihkal/pihkal160.shtml
  2. ^abcdefghShulgin A, Manning T, Daley P (2011).The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley:Transform Press.ISBN 978-0-9630096-3-0.
  3. ^Jacob P, Shulgin AT (1994)."Structure-Activity Relationships of the Classic Hallucinogens and Their Analogs". In Lin GC, Glennon RA (eds.).Hallucinogens: An Update(PDF). National Institute on Drug Abuse Research Monograph Series. Vol. 146. National Institute on Drug Abuse. pp. 74–91.PMID 8742795. Archived fromthe original on 13 July 2025.
  4. ^Shulgin AT (2003)."Basic Pharmacology and Effects". In Laing RR (ed.).Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137.ISBN 978-0-12-433951-4. Archived fromthe original on 13 July 2025.
  5. ^Glennon RA, Rosecrans JA (1982). "Indolealkylamine and phenalkylamine hallucinogens: a brief overview".Neuroscience and Biobehavioral Reviews.6 (4):489–497.doi:10.1016/0149-7634(82)90030-6.PMID 6757811.
  6. ^Glennon RA, Liebowitz SM, Anderson GM (March 1980). "Serotonin receptor affinities of psychoactive phenalkylamine analogues".Journal of Medicinal Chemistry.23 (3):294–299.doi:10.1021/jm00177a017.PMID 7365744.
  7. ^Glennon RA, Young R (October 1982). "Comparison of behavioral properties of di- and tri-methoxyphenylisopropylamines".Pharmacology, Biochemistry, and Behavior.17 (4):603–607.doi:10.1016/0091-3057(82)90330-6.PMID 6965276.
  8. ^Shulgin AT (May 1966). "The six trimethoxyphenylisopropylamines (trimethoxyamphetamines)".Journal of Medicinal Chemistry.9 (3):445–446.doi:10.1021/jm00321a058.PMID 5960939.
  9. ^"Controlled Drugs and Substances Act".Department of Justice Canada. Retrieved19 January 2026.

External links

[edit]
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Phenethylamines
Amphetamines
Phentermines
Cathinones
Phenylisobutylamines
(and further-extended)
Catecholamines
(and close relatives)
Cyclized
phenethylamines
Phenylalkylpyrrolidines
2-Benzylpiperidines
(phenidates)
Phenylmorpholines
(phenmetrazines)
Phenyloxazolamines
(aminorexes)
Isoquinolines and
tetrahydroisoquinolines
2-Aminoindanes
2-Aminotetralins
Others / unsorted
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=2,3,5-Trimethoxyamphetamine&oldid=1333832523"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2026 Movatter.jp